Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,112.79
    +33.93 (+0.42%)
     
  • Bitcoin USD

    64,446.41
    +867.48 (+1.36%)
     
  • CMC Crypto 200

    1,392.32
    -4.21 (-0.30%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,360.40
    +17.90 (+0.76%)
     
  • Crude Oil

    83.89
    +0.32 (+0.38%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Company News for Feb 3, 2023

  • Meta Platforms Inc.’s META shares soared 23.3% after the company reported fourth-quarter 2022 adjusted earnings per share of $3.00, surpassing the Zacks Consensus Estimate of $2.12.    

  • Bristol-Myers Squibb Co.’s BMY shares gained 2.2% after reporting fourth-quarter 2022 adjusted earnings per share of $1.82, outpacing the Zacks Consensus Estimate of $1.71.

  • Shares of Parker-Hannifin Corp. PH advanced 2.7% after posting second-quarter fiscal 2023 adjusted earnings per share of $4.76, exceeding the Zacks Consensus Estimate of $4.45.

  • Shares of Cardinal Health Inc. CAH rose 0.7% after the company posted second-quarter fiscal 2023 adjusted earnings per share of $1.32, beating the Zacks Consensus Estimate of $1.13.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report

Parker-Hannifin Corporation (PH) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Meta Platforms, Inc. (META) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research